Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Drop in Short Interest

Posted by Brenda Bartman on Jul 17th, 2026

Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 208,547 shares, a decline of 36.2% from the June 15th total of 327,052 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 188,004 shares, the days-to-cover ratio is presently 1.1 days.

Jyong Biotech Stock Performance

Shares of NASDAQ:MENS traded down $0.04 during midday trading on Friday, hitting $2.26. 33,907 shares of the stock were exchanged, compared to its average volume of 211,361. Jyong Biotech has a 12 month low of $1.43 and a 12 month high of $67.00. The business’s 50-day moving average price is $2.01 and its 200 day moving average price is $2.32.

Jyong Biotech (NASDAQ:MENS – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Institutional Trading of Jyong Biotech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in Jyong Biotech during the 3rd quarter worth approximately $67,000. Millennium Management LLC bought a new stake in shares of Jyong Biotech in the 3rd quarter valued at $512,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Jyong Biotech during the fourth quarter worth $49,000. Geode Capital Management LLC raised its stake in Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Jyong Biotech in the fourth quarter valued at $275,000.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Jyong Biotech presently has an average rating of “Sell”.

Read Our Latest Research Report on MENS

About Jyong Biotech

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.